Recent Quotes (30 days)

You have no recent quotes
chg | %

Resverlogix Corp.  

(Public, TSE:RVX)   Watch this stock  
Find more results for rvx
-0.030 (-3.70%)
Jul 23 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.75 - 0.87
52 week 0.41 - 1.16
Open 0.82
Vol / Avg. 184,299.00/48,077.00
Mkt cap 66.47M
P/E 1.44
Div/yield     -
EPS 0.54
Shares 85.21M
Beta 3.04
Inst. own     -

Key stats and ratios

Q1 (Jan '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets 1709.68% -263.82%
Return on average equity - -
Employees 40 -
CDP Score - -


Suite 202, 279 Midpark Way SE
+1-403-2549252 (Phone)
+1-403-2568495 (Fax)


Resverlogix Corp. is a clinical stage biotechnology company. The Company is engaged in developing compounds involving ApoA-I production. The Company is engaged in developing RVX-208, a small molecule being developed for clinical conditions for the treatment of atherosclerosis. RVX-208 is the first Bromodomain and ExtraTerminal domain (BET) inhibitor in clinical trials. New compounds from the Company´┐Żs epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases, including neurodegenerative diseases and diabetes mellitus.

Officers and directors

Peter Johann Ph.D. Independent Chairman of the Board
Donald J. McCaffrey President, Chief Executive Officer, Secretary, Director
A. Brad Cann CA Chief Financial Officer
F. Allan Gordon M.D., Ph.D. Senior Vice President - Clinical Development
Jan O. Johansson M.D., Ph.D. Senior Vice President - Medical Affairs
Kenneth Lebioda Senior Vice President - Business & Corporate Development
Gregory S. Wagner Ph.D. Senior Vice President - Research and Development
Norman Wong M.D. Chief Scientific Officer
Kelly B. McNeill Independent Director
Eldon R. Smith M.D. Independent Director
Age: 74